“In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for all cancers; these performance analyses were descriptive and the trial's primary late-stage-cancer endpoint was not met.”

0.9925 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else “In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for…” https://galedra.org/investigations/01a0eaa6-f9f2-756b-a63f-b75a4e467f90

“In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for all cancers; these performance analyses were descriptive and the trial's primary late-stage-cancer endpoint was not met.”

Supported · 0.9925 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card